Reference
- Cao J, Burke JE, Dennis EA. Using hydrogen/deuterium exchange mass spectrometry to define the specific interactions of the phospholipase a 2 superfamily with lipid substrates, inhibitors, and membranes. J Biol Chem. 2013;288:1806–1813.
- Dennis EA, Cao J, Hsu Y-H, et al. Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. Chem Rev. 2011;111:6130–6185.
- Vasquez AM, Mouchlis VD, Dennis EA. Review of four major distinct types of human phospholipase A2. Adv Biol Regulat Symposium Issue. 2018;67:212–218.
- Kokotou MG, Limnios D, Nikolaou A, et al. Inhibitors of phospholipase A2 and their therapeutic potential: an update on patents (2012-2016). Exp Opin Ther Patents. 2017;27:217–225.
- Magrioti V, Kokotos G. Phospholipase A2 inhibitors for the treatment of inflammatory diseases: a patent review (2010 – present). Exp Opin Ther Patents. 2013;23:333–344.
- Murakami M, Kambe T, Shimbara S, et al. Different functional aspects of the group II subfamily (types IIA and V) and type X secretory phospholipase A2s in regulating arachidonic acid release and prostaglandin generation: implications of cyclooxygenase-2 induction and phospholipid scramblase-mediated cellular membrane perturbation. J Biol Chem. 1999;274:31435–31444.
- Seilhamer JJ, Pruzanski W, Vadas P, et al. Cloning and recombinant expression of phospholipase A2 present in rheumatoid arthritic synovial fluid. J Biol Chem. 1989;264:5335–5338.
- Lättig J, Böhl M, Fischer P, et al. Mechanism of inhibition of human secretory phospholipase A2 by flavonoids: rationale for lead design. J Comput Aided Mol Des. 2007;21:473–483.
- Ong W-Y, Farooqui T, Kokotos G, et al. Synthetic and natural inhibitors of phospholipases A2: their importance for understanding and treatment of neurological disorders. ACS Chem Neurosci. 2015;6:814–831.
- Roohbakhsh A, Parhiz H, Soltani F, et al. Molecular mechanisms behind the biological effects of hesperidin and hesperetin for the prevention of cancer and cardiovascular diseases. Life Sci. 2015;124:64–74.
- Kim HP, Son KH, Chang HW, et al. Anti-inflammatory plant flavonoids and cellular action mechanisms. J Pharmacol Sci. 2004;96:229–245.
- Chandra DN, Prasanth GK, Singh N, et al. Identification of a novel and potent inhibitor of phospholipase A2 in a medicinal plant: crystal structure at 1.93Å and surface plasmon resonance analysis of phospholipase A2 complexed with berberine. Biochim Biophys Acta. 2011;1814:657–663.
- Rummey C, Metz G. Homology models of dipeptidyl peptidases 8 and 9 with a focus on loop predictions near the active site. Proteins. 2006;66:160–171.
- Harder E, Damm W, Maple J, et al. 2015. OPLS3: A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins.
- Halgren TA, Nachbar RB. Merck molecular force field. IV. Conformational energies and geometries for MMFF94. J Comput Chem. 1996;17:587–615.
- Jorgensen WL, Chandrasekhar J, Madura JD, et al. Comparison of simple potential functions for simulating liquid water. J Chem Phys. 1983;79:926–935.
- Li J, Abel R, Zhu K, et al. The VSGB 2.0 model: a next generation energy model for high resolution protein structure modeling. Proteins. 2011;79:2794–2812.
- Alterio V, Di Fiore A, D’Ambrosio K, et al. Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? Chem Rev. 2012;112:4421–4468.